Metabolomic analysis for scale-down model improvement by Garr, Eric
Engineering Conferences International
ECI Digital Archives
Cell Culture Engineering XV Proceedings
Spring 5-11-2016




Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv
Part of the Biomedical Engineering and Bioengineering Commons
This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture
Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Eric Garr, "Metabolomic analysis for scale-down model improvement" in "Cell Culture Engineering XV", Robert Kiss, Genentech
Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016).
http://dc.engconfintl.org/cellculture_xv/127
          Metabolomic Analysis for Scale-Down Model Improvement 
 
Eric R. Garr, Manufacturing Science and Technology, Bristol-Myers Squibb, eric.garr@bms.com 
Danny Maskas, Manufacturing Science and Technology, Bristol-Myers Squibb  
Danielle Harrison, Manufacturing Science and Technology, Bristol-Myers Squibb  
Simpson Gregoire, Manufacturing Technology, Bristol-Myers Squibb  
Itzcoatl Pla, Manufacturing Science and Technology, Bristol-Myers Squibb  
 
 
Key Words: Metabolomics, Lactate, Scale-down, Commercial, pCO2  
 
The use of scale-down models is essential for the development, characterization and continuous improvement 
of commercial cell culture processes. A model demonstrated to be predictive of large-scale performance is 
advantageous as small-scale data can be used to support process investigations and changes, reduce costs 
and consequently accelerate new therapies to market. Aligning geometric aspect ratios and dimensionless 
engineering parameters improved the overall scale-down model representation for key process outputs such as 
pCO2 accumulation and cell viability. Despite these changes, the revised scale-down model did not fully match 
the large-scale process lactate accumulation.  Interestingly, it was demonstrated that pCO2 accumulation at 
small-scale reduced net lactate consumption, however pCO2 accumulation alone was not sufficient to fully 
match the absence of metabolic shift observed at large-scale. Small-scale pH ranging studies demonstrated that 
at settings above the large-scale process set point, the scale-down reactors had lactate profiles more closely 
matching the commercial process. Conversely, a lower pH set point in the commercial-scale reactor combined 
with an improved sparging strategy to remove CO2 had a transient increase in net lactate consumption, falling 
short of a metabolic shift. Combined, these data suggest that physicochemical differences between small and 
large scale bioreactors are contributing to the differences in metabolic behavior seen in this process. A 
metabolomic approach was used to elucidate the root cause of metabolic difference between scales. A range of 
pH settings from 6.8-7.3 were evaluated in the 5L scale down model of the commercial process. Samples from 
the commercial process operated at different pH set points were also obtained and included in the study. 
Results of metabolic profiling and hypothesis explaining the metabolic differences observed between scales will 
be presented. 
 
 
